Sequential Secures $3.5M to Pioneer AI-Driven Skin Science
In a significant boost for data-driven skincare, the genomics company Sequential has announced a $3.5 million equity investment. This funding round, co-led by Sparkfood and Corundum Systems Biology with participation from several other venture firms, will fuel the development of a groundbreaking AI-powered discovery platform. The goal is to systematically uncover the next generation of highly effective, scientifically validated skincare ingredients.
From Complex Data to Clear Skincare Solutions
Sequential stands out by using non-invasive testing to measure how products alter both the skin's microbiome and its molecular biomarkers. Their proprietary platform transforms this complex biological information into clear, actionable insights for product developers. This approach allows brands to create credible and effective formulations backed by robust clinical evidence. The company has already built one of the industry's most comprehensive datasets, comprising over 50,000 samples and insights from more than 10,000 participants worldwide.
An AI Engine Built on Real-World Evidence
The new capital will be used to construct an AI discovery engine directly on top of this vast clinical dataset. This technology aims to predict, optimize, and discover novel bioactive ingredient combinations that go beyond incremental improvements. "By applying artificial intelligence to one of the world’s largest clinical datasets in dermatological health, we can move beyond incremental formulation improvements and instead systematically design and validate breakthrough ingredient combinations," said Oliver Worsley, PhD, CEO and Co-Founder of Sequential. He emphasized the company's mission to bring pharmaceutical-grade evidence and computational precision to personal care.
Investors See a Transformative Bridge in Biology
Investors are backing this vision for a new standard in the industry. Anouk Veber, Ventures’ Business Unit Leader at Sparkfood, noted that Sequential has built a unique bridge between biology, clinical validation, and consumer product development. "We believe their AI-driven platform will reshape how next-generation personal care products are developed and differentiated," Veber stated. Similarly, Hidehiko Otake, CEO of Corundum Systems Biology, expressed that Sequential's mission aligns with their own to transform human health with large datasets, the microbiome, and AI.
Setting a New Standard for Personal Care Innovation
By uniting systems biology, clinical research, and advanced computational modeling, Sequential is poised to redefine innovation in skincare and adjacent health categories. The company plans to expand its biomarker discovery programs and global partnerships, building a scalable engine designed to unlock scientifically proven complexes. This work holds particular promise for inflammatory skin conditions like acne, atopic dermatitis, and rosacea, offering a hopeful path toward more targeted and effective solutions for millions of people.